Recent Advances in Cancer Genetics

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This Genetic Technology TOE depicts trends across cancer genetics. Constituting a genetic disorder in which the normal control of cell growth is significantly altered, cancer disease represents one of the most globally concerned fields of research. Cancer treatment and diagnostics may find a new hope in cancer genetics, which explains the rapid expansion of this discipline across medical specialties. The corresponding clinical trial analysis is depicted along with industry interactions. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, j

Table of Contents

Recent Advances in Cancer GeneticsTechnology ProfilesGenomic Companion Diagnostic Platform for Prostate CancerCost-effective Companion Diagnostic for Checkpoint Inhibitor TherapyLeveraging Human Fibroblasts for Neural Stem Cell-based TherapyEpigenetics Insights across Ewing SarcomaAppendixClinical Trial AnalysisIndustry Interactions

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.